IL5 and eosinophilic esophagitis: Indeed, anti-Il-5 monoclonal antibodies (i.e., reslizumab or mepolizumab), which are effective in blocking IL-5, have been ineffective in treating symptoms and inflammation in EoE in both children and adults [61,62].